This is a prospective, single-arm, phase II study. Patients will be treated with an
allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body
irradiation (TBI) conditioning with different melphalan and TBI doses based on patient-
and disease-related risk.
Additional locations may be listed on ClinicalTrials.gov for NCT06028828.
Locations matching your search criteria
United States
California
Orange
UC Irvine Health/Chao Family Comprehensive Cancer CenterStatus: Active
Contact: Stefan O Ciurea
Phone: 877-827-8839
Eligible patients will receive an allogeneic stem cell transplantation using a
combination of fludarabine, melphalan and total body irradiation (TBI) conditioning
regimen and post-transplant high dose cyclophosphamide (PTCY), tacrolimus and
mycophenolate mofetil (MMF) for graft-versus-host prophylaxis.
Melphalan and TBI doses will be tailored based on the Hematopoietic Stem Cell Transplant-
Composite Risk (HCT-CR), age and Karnofski performance status (KPS). Melphalan dose
ranges from 100 -140 mg/m2 while TBI dose ranges from 2-5 Gy.
All patients will be monitored for safety and efficacy up to 2 years
post-transplantation.
Lead OrganizationUC Irvine Health/Chao Family Comprehensive Cancer Center
Principal InvestigatorStefan Octavian Ciurea